Sobre o negócio do cancro e porque é que os SNSs deviam apostar muito mais na prevenção do que no tratamento, as respostas estão por todo o lado:
http://www.stardailystandard.com/breaking/novartis-lymphoma-research-exhibits-cart-on-monitor-for-2017-us-submission/43165/
Nomeadamente no meio milhão de dólares por doente (custo estimado pelos peritos):
Citando:
"With CTL019, also being studied by Novartis on children with advanced leukemia, the Basel-based drug giant has joined smaller rivals including Juno Therapeutics and Kite Pharma seeking to launch new, more-effective – and likely very expensive – treatments for blood cancers.
Analysts expect CART therapies to command prices up to US$450,000 when they hit the market by 2017. Novartis acknowledged costs will be high, but declined to give dimensions
(...)"
